Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Innovent starts China’s first trial of a novel cancer immunotherapy

By Jonathan Chan June 2, 2020

Reprints
oral squamous carcinoma cell
Human oral squamous carcinoma cell Anne Weston/Francis Crick Institute/Wellcome

Cancer drug developer Innovent Biologics started an early-stage clinical trial for its monoclonal antibody IBI939, the first anti-TIGIT drug to be tested in China.

The Suzhou biotech is hoping to develop the antibody into a potential treatment for advanced forms of cancer, either as a monotherapy or in combination with Tyvyt, its approved PD-1 drug for Hodgkin’s lymphoma.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Jonathan Chan

China Health Care Writer

Tags

Experts weigh in on potential health hazards posed by…
Experts weigh in on potential health hazards posed by chemicals in Ohio train derailment
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Patient groups balk at former AstraZeneca official negotiating U.K.-India…
Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
Altimmune’s obesity drug fails to stand out from blockbuster…
Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
Pharmalittle: FDA official wants to use accelerated approval for…
Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax…
A new Medicare ruling could give virtual reality companies…
A new Medicare ruling could give virtual reality companies an easier path to payment

Recommended Stories